Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 13;11:4053. doi: 10.1038/s41467-020-17697-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Clinical history of the patient corresponding to HBCx-180 PDX: the patient was treated by neo-adjuvant chemotherapy and adjuvant chemotherapy + endocrine treatment (tamoxifen and letrozole). The patient recurred with bone metastases 14 years after diagnosis and was treated by palbociclib + letrozole during 3 months followed by paclitaxel before vertebroplasty and PDX establishment. b Immunohistochemical analysis of Ki67 (54% of positive cells), PLK1 (10% of positive cells), ER (95% of positive cells) and phospho-RB (37% of positive cells) in PDX HBCx-180 and copy number profile (Cytoscan HD array). c Response to fulvestrant, palbociclib, palbociclib and fulvestrant and volasertib in PDX HBCx-180. Mean ± SD (n = 5 fulvestrant treated group; n = 6 in the other groups). P ≤ 0.0001 (Mann–Whitney t test, volasertib versus palbo + fulv., two-sided). d Clinical history of the patient corresponding to HBCx-176 PDX: the breast tumour was removed by tumorectomy and was ER+ PR−. The patient did not received adjuvant endocrine treatment, recurred with bone, liver and lung metastases 14 years after diagnosis and was treated by palbociclib + letrozole during 3 months before vertebroplasty and PDX establishment. e IHC analysis of ER (0% of positive cells), Ki67 (54% of positive cells), P-ERK (70% of positive cells) and P-RB (47% of positive cells) and copy number profile (Cytoscan HD array). f Response to trametinib, palbociclib and volasertib in PDX HBCx-180. Mean ± SD; n = 7 for control, palbociclib, volasertib, n = 8 in trametinib group. P ≤ 0.0001 (Mann–Whitney t test, volasertib versus palbo + fulv.).